NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] AstraZeneca PostDoc fellow opportunity

From: Yates, James W T <James.Yates_at_astrazeneca.com>
Date: Tue, 27 Mar 2018 12:13:05 +0000

N=1 Patient Derived Xenograft Trials: Understanding the relationship betw=
een tumour growth rate and drug sensitivity for efficient translation and p=
atient selection

https://astrazeneca.wd3.myworkdayjobs.com/Emerging-Talent/job/UK---Cambridg=
e/Post-Doc-Fellow---Effective-translation-by-modelling-mouse-trials_R-02355=
1-1

We're currently looking for talented scientists to join our innovative acad=
emic-style Postdoc. From our centre in Cambridge, UK, you'll be in a global=
 pharmaceutical environment, contributing to live projects right from the s=
tart. You'll take part in a comprehensive training programme, including a f=
ocus on drug discovery and development, given access to our existing Postdo=
ctoral research, and encouraged to pursue your own independent research in =
cutting edge laboratories. It's a newly expanding programme spanning a rang=
e of therapeutic areas across a wide range of disciplines.
What's more, you'll have the support of a leading academic advisor, based a=
t the University of Cambridge, who'll provide you with the guidance and kno=
wledge you need to develop your career. This is an exciting area that hasn'=
t been explored to its full potential, making this an opportunity to make a=
 real difference to the future of medical science.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that =
focuses on the discovery, development and commercialisation of prescription=
 medicines for some of the world's most serious diseases. But we're more th=
an one of the world's leading pharmaceutical companies. At AstraZeneca, we'=
re proud to have a unique workplace culture that inspires innovation and co=
llaboration. Here, employees are empowered to express diverse perspectives =
- and are made to feel valued, energised and rewarded for their ideas and c=
reativity.
Cancer is one of the greatest challenges facing medical science today. In o=
ur Oncology Team, you'll push the boundaries of science every day to overco=
me that challenge. We've been at the centre of some of the biggest breakthr=
oughs in oncology. In lung cancer, for example, we've brought together comp=
lementary expertise to aid discovery and accelerate development in new medi=
cines through a variety of partnerships and initiatives. We're also early a=
dopters of new technologies to support innovation, including CRISPR, genome=
 editing techniques and a next-generation sequencing platform for companion=
 diagnostics in oncology. But we're not stopping there. With a world-class =
pipeline and some of the best experts in the industry, we're in a great pos=
ition to develop even more innovative therapeutic approaches.
You will improve the treatment of cancer patients by harnessing mouse trial=
 data with a combination of bioinformatics and mechanistic modelling. These=
 studies reproduce the disease heterogeneity observed in a human patient po=
pulation. You will be investigating how the underlying growth kinetics of t=
hese engrafted tumours alters response to treatment.
You will develop methodology to design and interpret patient-derived xenogr=
aft (PDX) mouse trial data sets including mathematical models of treatment =
effect on tumour size over time that reflect the underlying disease biology=
.
Education and Experience Required:
Essential:

  * Phd in mathematics, physics or engineering with a focus on biomedical=
 research
  * Proven written and oral communication skills
  * Aptitude for interdisciplinary research
Desirable:

  * Experience of bioinformatics, machine learning, PKPD and mathematical=
 tumour disease modelling
  * Previous work with preclinical datasets
Skills and Capabilities required:

  * Experience developing mathematical models using real experimental dat=
a. Use of R for statistics.
  * Understanding of ordinary differential equation models.
  * Experience with Matlab and NONMEM desirable
This is a 3 year programme. 2 years will be a Fixed Term Contract, with a 1=
 year extension which will be merit based. The role will be based at Cambri=
dge UK with a competitive salary on offer
To apply for this position, please click the apply link below.
Advert closing date - 13th May 2018
AstraZeneca welcomes applications from all sections of the community.
AstraZeneca is an equal opportunity employer. AstraZeneca will consider all=
 qualified applicants for employment without discrimination on grounds of d=
isability, sex or sexual orientation, pregnancy or maternity leave status, =
race or national or ethnic origin, age, religion or belief, gender identity=
 or re-assignment, marital or civil partnership status, protected veteran s=
tatus (if applicable) or any other characteristic protected by law.
If you share our passion for scientific excellence, find out more at; https=
://careers.astrazeneca.com/students/programmes/post-doctoral-programmes
________________________________

AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number:03674842 and its registered office at 1 Francis Crick Ave=
nue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient =
only and may contain confidential and privileged information. If they have =
come to you in error, you must not copy or show them to anyone; instead, pl=
ease reply to this e-mail, highlighting the error to the sender and then im=
mediately delete the message. For information about how AstraZeneca UK Limi=
ted and its affiliates may process information, personal data and monitor c=
ommunications, please see our privacy notice at www.astrazeneca.com<https:/=
/www.astrazeneca.com>


Received on Tue Mar 27 2018 - 08:13:05 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com. Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.